Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma

Journal of Pathology

Volumn 235, Issue 3, 2015, Pages 456-465

  Yap, Lee Fah ^a,b   Velapasamy, Sharmila ^a   Lee, Hui Min ^a   Thavaraj, Selvam ^c   Rajadurai, Pathmanathan ^d   Wei, Wenbin ^b   Vrzalikova, Katerina ^b   Ibrahim, Maha Hafez ^b   Khoo, Alan Soo Beng ^e   Tsao, Sai Wah ^f   Paterson, Ian C ^a   Taylor, Graham S ^b   Dawson, Christopher W ^b   Murray, Paul G ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SUBANG JAYA MEDICAL CENTRE   (Malaysia)

^e INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epstein Barr virus; Lpa receptor; Lysophosphatidic acid; Nasopharyngeal carcinoma

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 5; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; LPAR5 PROTEIN, HUMAN; LYSOPHOSPHOLIPID; MATRIX PROTEIN; PHOSPHODIESTERASE;

ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; NASOPHARYNX CARCINOMA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NASOPHARYNX TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; LYSOPHOSPHOLIPIDS; NASOPHARYNGEAL NEOPLASMS; PHOSPHORIC DIESTER HYDROLASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 84920742642     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4460     Document Type: Article

References (24)

1. Razak AR, Siu LL, Liu FF, et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010; 46: 1967-1978.
2. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22: 4604-4612.
3. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-698.
4. Lin CL, Lo WF, Lee TH, et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958.
5. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011; 30: 125-140.
6. Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-186.
7. Allen MD,Young LS,Dawson CW. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 2005; 79: 1789-1802.
8. Tsang CM, Zhang G, Seto E, et al. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int J Cancer 2010; 127: 1570-1583.
9. Port RJ, Pinheiro-Maia S, Hu C, et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol 2013; 231: 367-377.
10. Baumforth KR, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005; 106: 2138-2146.
11. Bose S, Yap LF, Fung M, et al. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J Pathol 2009; 217: 345-352.
12. Long HM, Haigh TA, Gudgeon NH, et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005; 79: 4896-4907.
13. Icheva V, Kayser S,WolffD, et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31: 39-48.
14. Hu C, Wei W, Chen X, et al. A global view of the oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis at the genetic and expression levels. PLoS One 2012; 7: e41055.
15. Jongsma M, Matas-Rico E, Rzadkowski A, et al. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One 2011; 6: e29260.
16. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nature Rev Cancer 2003; 3: 582-591.
17. Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-1642.
18. Lee Z, Cheng CT, Zhang H, et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008; 19: 5435-5445.
19. Lee CW, Rivera R, Gardell S, et al. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006; 281: 23589-23597.
20. Kotarsky K, Boketoft A, Bristulf J, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 2006; 318: 619-628.
21. Kloster MM, Hafte TT, Moltzau LR, et al. EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. Cell Signal 2008; 20: 1169-1178.
22. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 2012; 22: 144-153.
23. Li J, Zeng XH, Mo HY, et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007; 2: e1122.
24. Oda SK, Strauch P, Fujiwara Y, et al. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol Res 2013; 1: 245-255.